急性脑损伤患者的限制性与开放性输血策略:TRAIN随机临床试验
TRAIN为多中心、3期、平行组、开放标签随机临床试验,在22个国家72个ICU纳入伤后10天内血红蛋白<9 g/dL的创伤性脑损伤、动脉瘤性蛛网膜下腔出血或脑出血患者,随机接受开放性(血红蛋白<9 g/dL触发,n=408)或限制性(<7 g/dL触发,n=442)输血策略28天。主要终点为180天格拉斯哥结局扩展量表1-5分的不良神经功能结局,开放性组246/393(62.6%)vs 限制性组300/413(72.6%)(绝对差-10.0%[95%CI -16.5%至-3.6%];校正相对危险度0.86[95%CI 0.79-0.94];P=.002)。开放性组脑缺血事件35/397(8.8%)vs 限制性组57/423(13.5%)(相对危险度0.65[95%CI 0.44-0.97])。
要点
- 急性脑损伤合并贫血患者,开放性输血(血红蛋白<9 g/dL触发)较限制性(<7 g/dL触发)180天不良神经功能结局更少:62.6% vs 72.6%,绝对差-10.0%(95%CI -16.5%至-3.6%),校正RR 0.86(95%CI 0.79-0.94),P=.002。
- 脑缺血事件开放性组8.8%(35/397)低于限制性组13.5%(57/423),RR 0.65(95%CI 0.44-0.97)。
- 开放性组输血中位数2单位(IQR 1-3),限制性组0单位(IQR 0-1),绝对均值差1.0单位(95%CI 0.87-1.12)。
- 预设亚组中输血阈值对180天神经功能结局的影响一致。
适用人群与场景
- 创伤性脑损伤、动脉瘤性蛛网膜下腔出血或脑出血患者,伤后10天内血红蛋白<9 g/dL,预期ICU停留至少72小时。
- 多中心、3期、平行组、研究者发起、实用性、开放标签随机临床试验,在22个国家72个ICU进行,入组时间2017年9月1日至2022年12月31日,末次随访2023年6月30日。
诊断标准与关键阈值
- 开放性输血策略:血红蛋白<9 g/dL触发输血,28天期间。
- 限制性输血策略:血红蛋白<7 g/dL触发输血,28天期间。
- 主要终点:随机化后180天格拉斯哥结局扩展量表评分1-5分定义为不良神经功能结局。
处置流程与药物剂量
- 开放性策略组接受红细胞输注中位数2单位(IQR 1-3),限制性策略组中位数0单位(IQR 0-1),绝对均值差1.0单位(95%CI 0.87-1.12)。
红旗征与不能漏的情况
- 预设的14项严重不良事件包括随机化后脑缺血事件;开放性组脑缺血事件35/397(8.8%),限制性组57/423(13.5%)(RR 0.65[95%CI 0.44-0.97])。
研究设计与关键结果
- 多中心、3期、平行组、研究者发起、实用性、开放标签随机临床试验,22个国家72个ICU,850例随机(开放性n=408,限制性n=442),820例完成试验(平均年龄51岁;376[45.9%]女性),806例有主要终点数据(开放性393例,限制性413例)。
- 主要终点:180天不良神经功能结局开放性组246/393(62.6%)vs 限制性组300/413(72.6%),绝对差-10.0%(95%CI -16.5%至-3.6%),校正相对危险度0.86(95%CI 0.79-0.94),P=.002。
- 次要终点:脑缺血事件开放性组35/397(8.8%)vs 限制性组57/423(13.5%),相对危险度0.65(95%CI 0.44-0.97)。
- 预设亚组中输血阈值对180天神经功能结局的影响一致。
证据类型、等级与局限
- 证据类型:多中心、3期、平行组、研究者发起、实用性、开放标签随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急性脑损伤(创伤性脑损伤、动脉瘤性蛛网膜下腔出血或脑出血)合并贫血(血红蛋白<9 g/dL)且预期ICU停留至少72小时的患者,采用开放性输血策略(血红蛋白<9 g/dL触发)较限制性策略(<7 g/dL触发)可减少180天不良神经功能结局,作者认为开放性输血策略可能更优。
指南或共识出处
- TRAIN随机临床试验(ClinicalTrials.gov标识符NCT02968654),发表于JAMA。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Blood transfusions are commonly administered to patients with acute brain injury. The optimal hemoglobin transfusion threshold is uncertain in this patient population.
OBJECTIVE: To assess the impact on neurological outcome of 2 different hemoglobin thresholds to guide red blood cell transfusions in patients with acute brain injury.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, phase 3, parallel-group, investigator-initiated, pragmatic, open-label randomized clinical trial conducted in 72 intensive care units across 22 countries. Eligible patients had traumatic brain injury, aneurysmal subarachnoid hemorrhage, or intracerebral hemorrhage; hemoglobin values below 9 g/dL within the first 10 days after injury; and an expected intensive care unit stay of at least 72 hours. Enrollment occurred between September 1, 2017, and December 31, 2022. The last day of follow-up was June 30, 2023.
INTERVENTIONS: Eight hundred fifty patients were randomly assigned to undergo a liberal (transfusion triggered by hemoglobin <9 g/dL; n = 408) or a restrictive (transfusion triggered by hemoglobin <7 g/dL; n = 442) transfusion strategy over a 28-day period.
MAIN OUTCOMES AND MEASURES: The primary outcome was occurrence of an unfavorable neurological outcome, defined as a Glasgow Outcome Scale Extended score between 1 and 5, at 180 days following randomization. There were 14 prespecified serious adverse events, including occurrence of cerebral ischemia after randomization.
RESULTS: Among 820 patients who completed the trial (mean age, 51 years; 376 [45.9%] women), 806 had available data on the primary outcome, 393 in the liberal strategy group and 413 in the restrictive strategy group. The liberal strategy group received a median of 2 (IQR, 1-3) units of blood, and the restrictive strategy group received a median of 0 (IQR, 0-1) units of blood, with an absolute mean difference of 1.0 unit (95% CI, 0.87-1.12 units). At 180 days after randomization, 246 patients (62.6%) in the liberal strategy group had an unfavorable neurological outcome compared with 300 patients (72.6%) in the restrictive strategy group (absolute difference, -10.0% [95% CI, -16.5% to -3.6%]; adjusted relative risk, 0.86 [95% CI, 0.79-0.94]; P = .002). The effect of the transfusion thresholds on neurological outcome at 180 days was consistent across prespecified subgroups. In the liberal strategy group, 35 (8.8%) of 397 patients had at least 1 cerebral ischemic event compared with 57 (13.5%) of 423 in the restrictive strategy group (relative risk, 0.65 [95% CI, 0.44-0.97]).
CONCLUSIONS AND RELEVANCE: Patients with acute brain injury and anemia randomized to a liberal transfusion strategy were less likely to have an unfavorable neurological outcome than those randomized to a restrictive strategy.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02968654.
参考来源
- Taccone FS, Rynkowski CB, Møller K, et al. Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial. JAMA. 2024. PMID: 39382241. doi:10.1001/jama.2024.20424
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。